Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma.

Drecoll, Enken; Nitsche, Ulrich; Bauer, Karina; Berezowska, Sabina Anna; Slotta-Huspenina, Julia; Rosenberg, Robert; Langer, Rupert (2014). Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma. International journal of colorectal disease, 29(6), pp. 663-671. Springer 10.1007/s00384-014-1857-3

[img] Text
art%3A10.1007%2Fs00384-014-1857-3.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (686kB) | Request a copy

PURPOSE The molecular chaperone heat shock protein 90 (HSP90) plays an important role in several types of tumors also participating in the modulation of the activity of receptor tyrosine kinases activity such as members of the Her family. We evaluated the significance of HSP90 and Her2 expression in colon cancer. METHODS HSP90 and Her2 expression was determined by immunohistochemistry and by fluorescence in situ hybridization (FISH) on 355 primary resected colon carcinomas. Results were correlated with pathologic features (Union for International Cancer Control (UICC) pTNM category, tumor localisation, tumor differentiation), additional molecular genetic characteristics (BRAF, KRAS mutational status, mismatch repair genes (MMR)), and survival. RESULTS HSP90 immunoreactivity was observed in various degrees. Fifty-one cases (14 %) were positive for Her2 (score 2+ and 3+) with 16/43 cases with Her2 2+ staining pattern showing amplification of Her2 determined by FISH. There was a significant correlation between high HSP90 expression and Her2 overexpression (p = 0.011). High HSP90 expression was associated with earlier tumor stages (p = 0.019), absence of lymph node (p = 0.006), and absence of distant metastases (p = 0.001). Patients with high tumoral HSP90 levels had a better survival (p = 0.032), but this was not independent from other prognostic relevant pathologic parameters. Her2 expression was not associated with any of the investigated histopathological, molecular, or clinical parameters. CONCLUSIONS High HSP90 levels are reflecting lower malignant potential in colon cancer. Her2 positivity can be observed in a small number of cases. Targeting HSP90 and/or Her2 may be an alternative therapeutic approach in colon cancer in a subset of patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

02 Faculty of Law > Management im Gesundheitswesen (MIG)
04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology

UniBE Contributor:

Nitsche, Ulrich; Berezowska, Sabina Anna and Langer, Rupert

Subjects:

300 Social sciences, sociology & anthropology > 360 Social problems & social services
500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

1432-1262

Publisher:

Springer

Language:

English

Submitter:

Doris Haefelin

Date Deposited:

16 Feb 2015 16:04

Last Modified:

05 Nov 2015 13:53

Publisher DOI:

10.1007/s00384-014-1857-3

PubMed ID:

24733427

BORIS DOI:

10.7892/boris.63242

URI:

https://boris.unibe.ch/id/eprint/63242

Actions (login required)

Edit item Edit item
Provide Feedback